Pharmacy Value Management
Expert articles and analysis related to pharmacy value management.
AI Summary — Last 30 Days
CMS is moving pharmacy cost control further into mandatory value-based payment: the Trump administration finalized the GLOBE Part B drug payment model, but narrowed its scope and projected savings, while PhRMA’s lawsuit signals that drug-pricing demonstrations will remain a major litigation and operational risk for providers, manufacturers, and ACO-aligned specialty care networks (AAPC on GLOBE). At the same time, CMS is pairing MA/PDP market restructuring with PBM transparency and flat-fee proposals, as 4.3 million Medicare beneficiaries face plan terminations at the end of 2026—creating near-term attribution, formulary, medication-adherence, and care-navigation risk for VBC organizations managing senior populations (KFF analysis). The strategic throughline is a shift from rebate- and volume-driven pharmacy economics toward regulated, outcomes-oriented drug payment and benefit design, with hospitals, oncology groups, MA plans, PBMs, and 340B entities repositioning around margin protection and medication access.
Related Articles
CMS Finalizes GLOBE Drug Payment Model
When Negotiated Prices Become The Benchmark: Prior MFPs And The Vanishing Role Of Value
When Negotiated Prices Become The Benchmark: Prior MFPs And The Vanishing Role Of Value Health Affairs
PhRMA Sues to Block CMS Most Favored Nation Model for Part B
Drug pricing and affordabilityBeyond Medicare: How Part B drug negotiation may reshape commercial reimbursementinThought leadershipbyBrooke Fruman, Kolton Gustafson, Maddi Davidson, Markas EliasOct 2, 2026
Drug pricing and affordability
PhRMA sues Trump administration over GLOBE drug pricing demo program
The pharma industry is yet again taking the government to court over its latest effort to control US drug prices. Last week, the Trump administration finalized a demonstration program, called GLOBE,...
STAT+: PhRMA sues over Trump policy mandating lower drug prices in Medicare
The brand drug industry’s main trade group is suing the Trump administration over a pilot program tying Medicare drug prices to those in peer countries.
Why PhRMA Sued to Block Medicare's GLOBE Pricing Model
Trump Drug Pricing and the Iron Lung Fallacy
Trump Drug Pricing and the Iron Lung Fallacy American Enterprise Institute - AEI
Scope, Financial Impact of GLOBE Part B Drug Pricing Model Narrowed in Final Rule
Scope, Financial Impact of GLOBE Part B Drug Pricing Model Narrowed in Final Rule American Society of Clinical Oncology - ASCO
340B rebate model takes shape for 2027 with 10 manufacturers, 21 drugs
The new rebate model for the 340B Drug Pricing Program took a step closer to implementation Oct. 1 with the announcement of the initial cohort of participating manufacturers and covered drugs. The Hea...